In the third installment of the InvestmentNews four-part Lifestage series, we focus on those 60 to 75 — people on the verge of retiring and those who are in the first stage of retirement.
Standard & Poor's Equity Research recently upgraded its outlook for the biotechnology industry to positive from neutral.
Steven Silver, S&P's biotechnology equity analyst, thinks the industry is positioned for renewed investor interest in 2010.
